is Íslenska en English

Grein

Háskóli Íslands > Heilbrigðisvísindasvið > Rit starfsmanna >

Vinsamlegast notið þetta auðkenni þegar þið vitnið til verksins eða tengið í það: http://hdl.handle.net/1946/21931

Titill: 
  • Titill er á ensku Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin
Útgáfa: 
  • Júní 2005
Útdráttur: 
  • Útdráttur er á ensku

    An emerging paradigm holds that loss of negative signalling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG-6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells. Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signalling in breast epithelium may represent an advantageous condition during ErbB-driven tumorigenesis. Although mutational inactivation of the RALT gene was not detected in human breast carcinomas, RALT mRNA and protein expression was strongly and selectively reduced in ERBB2-amplified breast cancer cell lines. Reconstitution of RALT expression in ERBB2-amplified SKBr-3 and BT474 cells inhibited ErbB-2-dependent mitogenic signalling and counteracted the ability of ErbB ligands to promote resistance to the ErbB-2-targeting drug Herceptin. Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents.

Birtist í: 
  • Oncogene, (2005), 24, 4540-4548
ISSN: 
  • 0950-9232
Tengd vefslóð: 
  • http://www.nature.com/onc/journal/v24/n28/pdf/1208658a.pdf
  • http://web.a.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=376c18a6-b6ac-469d-a34c-a42eedeb2ea9%40sessionmgr4005&vid=1&hid=4101
  • http://search.proquest.com/docview/227355528/fulltextPDF/54D73E8A56A04144PQ/1?accountid=135775
  • http://www.readcube.com/articles/10.1038%2Fsj.onc.1208658
  • http://www.ncbi.nlm.nih.gov/pubmed/15856022
  • https://www.researchgate.net/publication/7882072_Loss_of_RALTMIG-6_expression_in_ERBB2-amplified_breast_carcinomas_enhances_ErbB-2_oncogenic_potency_and_favors_resistance_to_Herceptin
Samþykkt: 
  • 9.6.2015
URI: 
  • http://hdl.handle.net/1946/21931


Skrár
Skráarnafn Stærð AðgangurLýsingSkráartegund 
Anastasi2005.pdf399.35 kBOpinnHeildartextiPDFSkoða/Opna